Polar Asset Management Partners’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Polar Asset Management Partners’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500,000	Closed	–	–	803
2024 Q4	$0	Sell	500,000 -681,872	-58%	-$278K	﹤0.01%	845
2024 Q3	$258K	Buy	1,181,872 +101,872	+9%	+$90.4K	0.01%	483
2024 Q2	$1.28M	Hold	1,080,000	–	–	0.03%	369
2024 Q1	$2M	Hold	1,080,000	–	–	0.03%	359
2023 Q4	$2.94M	Buy	+1,080,000	New	+$3.49M	0.05%	314
2023 Q2	–	Sell	-300,000	Closed	-$3.04M	–	1089
2023 Q1	$3.04M	Hold	300,000	–	–	0.05%	455
2022 Q4	$3.02M	Hold	300,000	–	–	0.04%	549
2022 Q3	$2.92M	Hold	300,000	–	–	0.04%	638
2022 Q2	$2.91M	Hold	300,000	–	–	0.03%	641
2022 Q1	$2.91M	Hold	300,000	–	–	0.03%	573
2021 Q4	$2.91M	Hold	300,000	–	–	0.03%	552
2021 Q3	$2.91M	Buy	+300,000	New	+$2.93M	0.03%	517

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Polar Asset Management Partners's NKGN Position: Q1 2025 in Review

Polar Asset Management Partners sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 500,000 shares.

Polar Asset Management Partners first reported a position in NKGN in Q3 2021 and held it in 12 quarters. The position peaked at $3.04M in Q1 2023. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

Polar Asset Management Partners reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Polar Asset Management Partners sold 500,000 NKGen Biotech, Inc. Common Stock shares in Q1 2025.
Polar Asset Management Partners first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
Polar Asset Management Partners's NKGen Biotech, Inc. Common Stock position peaked at $3.04M in Q1 2023.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on Polar Asset Management Partners's 13F filing for Q1 2025, filed 15 May 2025.